Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab Vaccination Response in RA
NCT01163747Phase 4Completed
- Sponsor
- Genentech
- Start
- Sep 2010
- Primary completion
- Dec 2011
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of tocilizumab in rheumatoid arthritis (RA) (2 arms), sponsored by Genentech. Primary endpoint: Percentage of Participants Who Responded to ≥ 6 of 12 Anti-pneumococcal Antibody Serotypes at 8 weeks. Started Sep 2010; status: completed.
02
Drugs
tocilizumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT01163747.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01163747.